Providers fuel 'gray market'

Lee, Jaimy
September 2011
Modern Healthcare;9/5/2011, Vol. 41 Issue 36, p8
Trade Publication
The article discusses the rising number of drug shortages in the U.S. in August 2011, which has led to an increased focus on gray-market vendors and concerns about the safety and quality of products they are selling. It says that physician's offices, pharmacies and hospitals are both sellers and buyers feeding a gray market. According to hospital pharmacists, gray-market vendors purchase drugs from pharmacies and hospitals and then sell them to other hospitals with marked-up prices.


Related Articles

  • Compensation and Reimbursement.  // Best Practices for Hospital & Health-System Pharmacy;2014/2015, p417 

    The article discusses several policies related to compensation and reimbursement in pharmacy management in the U.S. Topics include payment authorization and coverage verification processes, drug product reimbursement, and revenue cycle compliance and management. Also provided are policies on...

  • FDA grants four-month delay for some track-and-trace provisions. Traynor, Kate // American Journal of Health-System Pharmacy;8/15/2015, Vol. 72 Issue 16, p1339 

    The article reports on the extension for the track-and-trace requirement under the Drug Supply Chain Security Act until November 1, 2015 by the U.S. federal agency Food and Drug Administration. Topics covered include the receipt, storage, and retrieval of product information that may be used for...

  • Developing a Bulletproof GXP Training Process from the Ground Up-A Case Study. Markovitz, David; Jones, David // Journal of GXP Compliance;Autumn2012, Vol. 16 Issue 4, p40 

    Many companies struggle with developing and implementing an effective good manufacturing practice (GMP) training process. There are several real and perceived obstacles that often get in the way of making a solid commitment to provide the training required by the GXP regulations. The cost of...

  • Government, Law, and Regulation.  // Best Practices for Hospital & Health-System Pharmacy;2010/2011, p158 

    The article focuses on the American Society of Health-System Pharmacists' (ASHP) policy on criteria for an intermediate category of drug products. An intermediate drug category can improve patient access to medications that offer substantial public health benefit but present challenges for...

  • Taking Preventive Action-- The Importance of Good Questions. Markovitz, David // Journal of GXP Compliance;Autumn2011, Vol. 15 Issue 4, p47 

    The article emphasizes the importance of asking good questions when taking corrective action and preventive action (CAPA) to avoid being cited by the U.S. Food and Drug Administration (FDA). Questions which can be answered by a yes or a no are characterized as inadequate and do not help...

  • ‘All of a sudden, there was fire'. Carlson, Joe; Rice, Sabriya // Modern Healthcare;7/14/2014, Vol. 44 Issue 28, p8 

    The article offers information on incident of surgical fire happens at FirstHealth Moore Regional Hospital in Pinehurst, North Carolina in which the fire emerges due to use of electrosurgical tools by doctors which ignites with alcohol-based disinfectant used in the incision site of patient. It...

  • Policy Watch. FDA faces congressional probes and more transparency and organizational changes. Wechsler, Jill // Formulary;Feb2011, Vol. 46 Issue 2, p66 

    The article reports on an increase in federal budget cuts and much more aggressive oversight of administration health policy and regulatory programs that the U.S. Food and Drug Administration is expecting in 20111 as a result of a Republican politician take over of the majority in the U.S. House...

  • Substitution in Regulatory Agencies: FDA Enforcement Alternatives. Olson, Mary // Journal of Law, Economics & Organization;Oct1996, Vol. 12 Issue 2, p376 

    This article develops a framework to understand the factors to which regulatory agencies respond and examines how these factors may influence agency decision-making. The model shows how either changing feedback from constituents or changing regulatory costs can alter the trade-offs facing the...

  • Impact of microarray data quality on genomic data submissions to the FDA. Frueh, Felix W. // Nature Biotechnology;Sep2006, Vol. 24 Issue 9, p1105 

    The article reports on the implications of microarray data quality on the submissions of genomic data to the U.S. Food and Drug Administration. The adoption and integration of genomic data in drug development is influenced by several factors including an understanding of the disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics